Investigated for use/treatment in cervical dysplasia/cancer, viral infection, and vulvar dysplasia and carcinoma.
- Mechanism
- Curator reviewed
TG 4001 is based on the modified vaccinia virus Ankara (MVA virus) carrying and expressing HPV16 E6 and E7 genes. The MVA vector is a highly attenuated strain of vaccinia virus that combines an extensive history of safety with the ability to stimulate a strong immune response to antigens. The TG 4001 therapeutic vaccine induces specific immunity by presentation of E6 and E7 antigens to T cells via major histocompatibility complex (MHC) class I and II inducing specific cellular and humoral responses. A second mechanism may be a non-specific activation of the immune system via the vaccinia virus and the interleukin 2 (IL2) adjuvant of the immune response. TG 4001 could have further applications beyond Cervical Intraepithelial Neoplasia (CIN) 2/3 as a single agent in low grade CIN (CIN1) or cervical cancers in combination with existing treatments. [Transgene press release]
- Primary indication
- Investigated for use/treatment in cervical dysplasia/cancer, viral infection, and vulvar dysplasia and carcinoma.Curator reviewed
- Also known as
- MVA-HPV-IL2 vaccine
- Code names
- R-3484 · RG 3484 · RO5217790 · TG-4001
Resolves to
What you can answer from here — as of June 12, 2020
Which companies are running trials of Tipapkinogene sovacivec, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account